<DOC>
	<DOC>NCT01516983</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of Icotinib at different dose levels in combination with whole brain radiotherapy for NSCLC patients with brain metastases and EGFR mutation.</brief_summary>
	<brief_title>Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation</brief_title>
	<detailed_description>The long-term control of brain metastases becomes a clinical challenge. Whole brain radiotherapy, the standard treatment for patients with multiple brain metastases, can only bring a modest survival improvement around 3-6 months. EGFR-TKIs like icotinib with its proven activity in non-small cell lung cancer may provide clinical benefits in such patients.</detailed_description>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Histological or cytological confirmation of nonsmall cell lung cancer (NSCLC). Diagnosis of brain metastases on a Gadoliniumenhanced MRI. More than 3 sites of intracranial metastases, or the longest diameter of the intracranial lesion is more than 3cm. Positive EGFR mutation. Previous usage of EGFRTKI or antibody to EGFR: gefitinib, erlotinib, herceptin, erbitux. CSF or MRI findings consistent with metastases of spinal cord, meninges or meningeal.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Safety</keyword>
	<keyword>EGFR-TKI</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Icotinib</keyword>
	<keyword>WBRT</keyword>
</DOC>